Recent Company News

• 10:01 AM ET Aug 11, 2025
  

  INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

• 08:34 AM ET Aug 19, 2025
  

  āshibio announces license agreement with Mereo BioPharma for vantictumab for the treatment of autosomal dominant osteopetrosis type 2 ($1.68, 0.00)

• 10:28 AM ET Aug 12, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (165 total)

• 07:38 AM ET Aug 12, 2025
  

  Mereo BioPharma Group reports Q2 EPS ($0.02) vs FactSet ($0.01) [6 est, ($0.02)-(0.01)] ($1.52, 0.00)